 |
|
First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
July 23, 2007The first genome-wide association study of an infectious disease, conducted by an international group of researchers through the Center for HIV/AIDS Vaccine Immunology (CHAVI), has yielded a new understanding of why some people can suppress virus levels following HIV infection. "The clearer picture of host responses to the virus achieved through this examination of genomes could lead to improved HIV therapies and provides new targets for vaccine developers," says Elias A. Zerhouni, M.D., director of the National Institutes of Health (NIH). CHAVI, which is led by Barton Haynes, M.D., of Duke University, Durham, N.C., was established in 2005 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
CHAVI's host genetics team, led by David Goldstein, Ph.D., also of Duke University, included scientists from several European countries and Australia who formed a consortium, EuroCHAVI, to perform this study. The investigators identified three gene variants, two of which are linked to an infected person's ability to control HIV viral load and a third that is implicated in disease progression to AIDS. The research is being published by Science on the Science Express Web site on Thursday, July 19.
"CHAVI is designed to foster collaborative research to overcome roadblocks that have impeded HIV vaccine development," says NIAID Director Anthony S. Fauci, M.D. "The insights into genetic factors influencing host control of HIV revealed by this work exemplify the power of such collective investigations."
Genome-wide association studies aim to identify genetic variations among people that can be tied to variations in disease susceptibility. Recent genome-wide association studies have found genetic markers linked to increased risk of such ailments as diabetes, cancer and heart disease. The CHAVI investigators are the first to apply genome-wide association techniques to an infectious disease.
"People vary greatly in their vulnerability to HIV infection," notes Dr. Haynes. "In particular, there are striking and largely unexplained differences between individuals in the degree to which they are able to hold viral levels to a low set point in the period soon after infection." If scientists could pinpoint the gene variants that help some people control HIV infection--or avoid it altogether--they might be able to rationally design therapies or vaccines to mimic these naturally occurring genetic advantages, he notes.
In 2006, CHAVI researchers launched an effort to pool genetic data from HIV-positive individuals who had enrolled in nine studies based throughout Europe and in Australia. Together, these studies contained information on more than 30,000 individuals. From this pooled cohort, the CHAVI scientists ultimately chose 486 DNA samples--representing the genomes of 486 HIV-positive people whose viral load set points had been carefully and accurately measured at multiple time points--for the genome-wide association study.
The scientists applied the genome samples to gene chips dotted with more than 550,000 human gene variants, called single nucleotide polymorphisms or SNPs. The sweep of genomes found three SNPs that were strongly associated with either viral load set point or disease progression. The two variants associated with viral load can explain 15 percent of the total variation among all infected individuals, the scientists estimate.
One of the identified variants is near a human immune gene called HLA-C, and may provide a new route for HIV vaccine developers to explore, says Dr. Goldstein. People with the identified variant are thought to make more of the gene's product than people who lack this presumably protective genetic variant. A consequence of this extra production of HLA-C protein, researchers hypothesize, is that the immune system is better able successfully identify and remove HIV-infected cells, thus keeping viral load set points low for long periods.
HIV has many ways to defend itself from immune system efforts to eliminate it. One defense is the ability of an HIV gene, nef, to decrease the production of two related immune system proteins, HLA-A and HLA-B. Nef, scientists believe, is not able to similarly hamper the expression of HLA-C. If scientists could design a vaccine to enhance HLA-C-mediated immune responses, they might be able to hit HIV at a vulnerable point, says Dr. Goldstein. Although HLA-C had previously been suspected of contributing to HIV control, this genome-wide study is the first to confirm the association, he adds.
The CHAVI investigators are currently building on these studies of polymorphisms to pinpoint the specific human gene variants that influence HIV replication.
"We applaud the CHAVI investigators for the highly collaborative nature of this work. It demonstrates that answers to important questions, requiring analysis of large amounts of clinical specimens, can be obtained quickly," says Peggy Johnston, Ph.D., director of NIAID's Vaccine Research Program.
NIH/National Institute of Allergy and Infectious Diseases
Genome-wide association studies aim to identify genetic variations among people that can be tied to variations in disease susceptibility. Recent genome-wide association studies have found genetic markers linked to increased risk of such ailments as diabetes, cancer and heart disease. The CHAVI investigators are the first to apply genome-wide association techniques to an infectious disease.
"People vary greatly in their vulnerability to HIV infection," notes Dr. Haynes. "In particular, there are striking and largely unexplained differences between individuals in the degree to which they are able to hold viral levels to a low set point in the period soon after infection." If scientists could pinpoint the gene variants that help some people control HIV infection--or avoid it altogether--they might be able to rationally design therapies or vaccines to mimic these naturally occurring genetic advantages, he notes.
In 2006, CHAVI researchers launched an effort to pool genetic data from HIV-positive individuals who had enrolled in nine studies based throughout Europe and in Australia. Together, these studies contained information on more than 30,000 individuals. From this pooled cohort, the CHAVI scientists ultimately chose 486 DNA samples--representing the genomes of 486 HIV-positive people whose viral load set points had been carefully and accurately measured at multiple time points--for the genome-wide association study.
The scientists applied the genome samples to gene chips dotted with more than 550,000 human gene variants, called single nucleotide polymorphisms or SNPs. The sweep of genomes found three SNPs that were strongly associated with either viral load set point or disease progression. The two variants associated with viral load can explain 15 percent of the total variation among all infected individuals, the scientists estimate.
One of the identified variants is near a human immune gene called HLA-C, and may provide a new route for HIV vaccine developers to explore, says Dr. Goldstein. People with the identified variant are thought to make more of the gene's product than people who lack this presumably protective genetic variant. A consequence of this extra production of HLA-C protein, researchers hypothesize, is that the immune system is better able successfully identify and remove HIV-infected cells, thus keeping viral load set points low for long periods.
HIV has many ways to defend itself from immune system efforts to eliminate it. One defense is the ability of an HIV gene, nef, to decrease the production of two related immune system proteins, HLA-A and HLA-B. Nef, scientists believe, is not able to similarly hamper the expression of HLA-C. If scientists could design a vaccine to enhance HLA-C-mediated immune responses, they might be able to hit HIV at a vulnerable point, says Dr. Goldstein. Although HLA-C had previously been suspected of contributing to HIV control, this genome-wide study is the first to confirm the association, he adds.
The CHAVI investigators are currently building on these studies of polymorphisms to pinpoint the specific human gene variants that influence HIV replication.
"We applaud the CHAVI investigators for the highly collaborative nature of this work. It demonstrates that answers to important questions, requiring analysis of large amounts of clinical specimens, can be obtained quickly," says Peggy Johnston, Ph.D., director of NIAID's Vaccine Research Program.
NIH/National Institute of Allergy and Infectious Diseases
Infectious Disease Current Events and Infectious Disease News RSSDNA barcodes: Creative new uses span health, fraud, smuggling, history, more
The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others.
Study reveals a 'missing link' in immune response to disease
The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.
Lessons from flu seasons past
Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons.
Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.
Important new novel 2009 H1N1 flu advisory for cardiopulmonary transplantation
Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.
MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition
MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2009 National Conference & Exhibition that add to the company's growing body of research on the burden of respiratory syncytial virus (RSV) on children, as well as pediatric infectious disease prevention.
Paradigm shift needed to combat drug resistance
When people travel, bacteria and other infectious agents travel with them. As about a billion people cross international borders each year, many more billions of the bugs come along for the ride.
Medical imaging may help researchers understand the pathogenesis of H1N1 virus
Researchers at the National Institutes of Health (NIH) have found that imaging can now be used as a tool for identifying severe cases of H1N1 and may play a key role in understanding the pathogenesis of the virus, possibly leading to earlier diagnoses of severe cases in the future.
Major discovery opens door to leishmania treatment
Leishmania is a deadly parasitic disease that affects over 12 million people worldwide, with more than 2 million new cases reported every year.
Water scarcity will create global security concerns
Water scarcity as a result of climate change will create far-reaching global security concerns, says Dr. Rajendra K. Pachauri, chair of the intergovernmental panel on climate change, a co-recipient of the 2007 Nobel Peace Prize.
More Infectious Disease Current Events and Infectious Disease News Articles
 |
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Expert Consult Premium Edition - Enhanced Online Features and Print by Gerald L. Mandell (Author) After thirty years, PPID is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. Mandell, Bennett, and Dolin have substantially revised and meticulously updated, this new edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition helps you identify and treat whatever infectious disease you see. And, as an Expert Consult title with enhanced online features, this updated 7th edition comes with convenient access to the full text online, regular... |
 |
Infectious Diseases: A Clinical Short Course, Second Edition (LANGE Clinical Medicine) by Frederick Southwick (Author) Gain a full understanding of clinical infectious diseases in just thirty days A Doody's Core Title! No other resource makes clinical infectious diseases more manageable and easy to master than Infectious Diseases: A Clinical Short Course. This one-of-a-kind self-instruction tool is organized by system/region as opposed to pathogens -- simulating how common pathogens and disorders would be encountered in rounds or in practice. For this reason, this remarkable resource is unsurpassed for learning how to associate pathogens with their corresponding impact on actual patients. Features: A true, concise “short course” format that can be read and understood in the span of a 30-day infectious disease rotation Numerous case examples... |
 |
Clinical Infectious Disease by David Schlossberg (Editor) This clinically-oriented, user-friendly text is the best on the market for infectious disease. Complete and comprehensive, Schlossberg's text will be an effective reference for any practitioner who may encounter these afflictions. The orientation of the volume is multi-faceted: in addition to the traditional organization of organ system and pathogen-related information, this text includes specific sections on the susceptible host, travel-related infections, nosocomial infections, infections related to trauma, and bioterrorism. The information on post-surgical infections will be of great interest to practicing surgeons. Informative algorithms, tables, and high-quality color photographs supplement many of the chapters in this conveniently-sized volume. For practicality and ease of use, one... |
 |
Infectious Disease: A Scientific American Reader (Scientific American Readers) by Scientific American (Editor) The international public health scare that resulted last year when a man infected with multidrug-resistant tuberculosis flew overseas from the United States and back illustrates both the fear and the potential impact of highly infectious diseases in a global age. At a time when scientists warn of the potential for an influenza epidemic to rival the deadly outbreak of 1919 and newspapers feature alarming headlines about incidences of mad cow disease, infectious disease will be a critical area of concern and scientific study in the twenty-first century. Infectious Disease collects thirty of the most exciting, innovative, and significant articles on communicable illness published in the pages of Scientific American magazine since 1993. With sections devoted to viral infections,... |
 |
Infectious Diseases, Second Edition (EXPERT GUIDE SERIES- AMERICAN COLLEGE OF PHYSICIANS) by James S. Tan (Editor), Michael J. Tan (Editor), Robert A. Salata (Editor), Thomas M. File Jr. (Editor) Here s the expert guidance practitioners need to diagnose and treat the most commonly encountered infections! This fully revised and updated New Edition keeps readers current with the latest etiologic agents, the most appropriate diagnostic tests, and the most effective management options. The 2nd Edition features new chapters on Antimicrobial Agents for the Primary Care Physician and Prosthetic Joint Infections. FEATURES: -Examines infections of the central nervous system, heart and blood vessels, gastrointestinal tract, genitourinary system, respiratory tract, skeletal system, and the skin. -Features individual chapters on HIV, herpes virus, Lyme disease, and malaria. -Puts key information at the reader s fingertips with diagnostic and treatment tables throughout the text. -Reviews... |
 |
Infectious Disease Epidemiology: Theory And Practice by Kenrad E., M.D. Nelson (Author), Carolyn F. Masters, Ph.D. Williams (Author) This thorough revision contains new chapters on principles of immunology, measles and polio, meningococcal infections, including pneumococcal, and influenza infections. The chapter on emerging infections has been divided into one of mosquito borne infections and includes West Nile Virus, Rift V and Dengue as well as other arthropod borne infections. SARS and Monkey Poxare included in the new chapter. All other chapters have been updated. |
 |
The A to Z of Infectious Diseases (Concise Encyclopedia) by Carol Turkington (Author), Bonnie Lee, M.d. Ashby (Author) In the past 25 years, more than 30 new germs affecting humans have emerged onto the medical scene, most of them rising from animals. New diseases like the avian flu, Ebola, SARS, and weaponized viruses such as anthrax and smallpox pose a growing danger to the world. With the threat of infectious diseases remaining constant, it is essential to have clear and concise information on this topic. "The A to Z of Infectious Diseases" provides more than 600 up-to-date entries covering the latest research, new treatments and vaccines, and rising diseases such as mad cow disease. Appendixes include drugs used to treat infectious diseases, tips for home disinfection, and lists of helpful organizations and publications, making this the ultimate resource for knowledge about infectious diseases. Topics... |
 |
Case Studies in Infectious Disease by Peter Lydyard (Author), Michael Cole (Author), John Holton (Author), Will Irving (Author), Nino Porakishvili (Author), Pradhib Venkatesan (Author), Kate Ward (Author) Case Studies in Infectious Disease presents forty case studies featuring the most important human infectious diseases worldwide. Written for students of microbiology and medicine this book describes the natural history of infection from point of entry of the pathogen through pathogenesis, followed by clinical presentation, diagnosis and treatment. Five core sets of questions are posed in each case. What is the nature of the infectious agent, how does it gain access to the body, what cells are infected, and how does the organism spread? What are the host defense mechanisms against the agent and how is the disease caused? What are the typical manifestations of the infection and the complications that can occur? How is the infection diagnosed and what is the... |
 |
Oxford Handbook of Infectious Diseases and Microbiology (Oxford Handbooks Series) by Estee Torok (Author), Ed Moran (Author), Fiona Cooke (Author) Reflecting the current approach to koint postgraduate training programs in infectious diseases (ID) and microbiology, the Oxford Handbook of Infectious Diseases and Microbiology takes an integrated approach to both subjects. It covers the basic principles of bacteriology and virology, along with specific guidance on individual diseases and conditions, all in the accessible Oxford Handbook style. Practical and comprehensive, this handbook includes coverage of National Frameworks and current legislation, together with information on topical issues such as bioterrorism and preventative medicine. Fully reviewed by specialist senior readers and with useful links to up-to-date clinical information and online resources, this is an important addition to the Oxford Handbook series. |
 |
Current Diagnosis & Treatment In Infectious Diseases (Current Diagnosis and Treatment in Infectious Diseases) by Walter R. Wilson (Author) Numerous quick-access boxes and tables summarize key information on one of the leading causes of death. This title covers the essentials of diagnosis, syndromes in children and adults, and treatments, including first and second-choice options. It blends practice-oriented, authoritative coverage with just the right amount of microbiology for understanding diagnostic and management decisions. |
| © 2009 BrightSurf.com |